Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5011023 | 0.91 | SLC6A4 (0.51) | SLC6A4ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL5010133 | 0.85 | SLC6A4 (0.58) | SLC6A4ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL16721029 | 0.82 | SLC6A4 (0.64) | SLC6A4ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL11081859 | 0.82 | SLC6A4 (0.69) | SLC6A4ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL6006319 | 0.82 | SLC6A4 (0.64) | SLC6A4ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL12506240 | 0.79 | SLC6A4 (0.65) | SLC6A4ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL3246866 | 0.79 | ALDH1A1 (0.54) | SLC6A4ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL6380326 | 0.79 | SLC6A4 (0.49) | SLC6A4ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL613009 | 0.78 | SLC6A4 (0.58) | SLC6A4ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL4949690 | 0.76 | CYP2C9 (0.47) | SLC6A4ALDH1A1CYP2C9CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207864-A1 | Organosilanes, Process For Production of the Same, and Use Thereof | SHARP KABUSHIKI KAISHA (JP) | 2008-08-28 | — | — | US | disclosed |
| US-6794365-B2 | INHIBITORS OF THE BLOOD CLOTTING ENZYME FACTOR XA; TREATING THROMBOEMBOLIC DISEASES; TRIFLUOROACETIC ACID SALT OF 2-(4-CARBAMIMIDOYL-BENZYL)-N-((1-CARBAMOYL-4-GUANIDINO-BUTYLCARBAMOYL) -CYCLOHEXYL-METHYL)-N',N'-DIMETHYL-MALONAMIDE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-21 | — | — | US | disclosed |
| US-6759420-B1 | LOW MOLECULAR WEIGHT, FACTOR XA SPECIFIC BLOOD CLOTTING INHIBITORS WITHOUT SIDE EFFECTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-06 | — | — | US | disclosed |
| CN-1406226-A | Novel malonic acid derivatives, process for their preparation, their use as inhibitors of factor XA activity and pharmaceutical compositions containing them | AVENTIS PHARMA GMBH (DE) | 2003-03-26 | — | — | CN | disclosed |
| EP-1265867-A1 | NOVEL MALONIC ACID DERIVATES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS INHIBITOR OF FACTOR XA ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma Deutschland GmbH (DE) | 2002-12-18 | — | — | EP | disclosed |
| US-6395737-B1 | ANTICOAGULANTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-05-28 | — | — | US | disclosed |
| US-20020022596-A1 | Novel malonic acid derivatives, processes for their preparation their use and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-02-21 | — | — | US | disclosed |
| CN-1332723-A | Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them | AVENTIS PHARMA GMBH (DE) | 2002-01-23 | — | — | CN | disclosed |
| CN-1332734-A | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity | AVENTIS PHARMA GMBH (DE) | 2002-01-23 | — | — | CN | disclosed |
| EP-1150946-A1 | ARYLALKANOYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma Deutschland GmbH (DE) | 2001-11-07 | — | — | EP | disclosed |
| EP-1140878-A1 | NOVEL MALONIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ( INHIBITIO OF FACTOR XA ACTIVITY ) | Aventis Pharma Deutschland GmbH (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001062735-A1 | NOVEL MALONIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS INHIBITOR OF FACTOR XA ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-30 | — | — | WO | disclosed |
| EP-1127884-A1 | Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them | Aventis Pharma Deutschland GmbH (DE) | 2001-08-29 | — | — | EP | disclosed |
| EP-1022268-A1 | Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them | Aventis Pharma Deutschland GmbH (DE) | 2000-07-26 | — | — | EP | disclosed |
| WO-2000040548-A1 | ARYLALKANOYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000040571-A1 | NOVEL MALONIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM (INHIBITION OF FACTOR XA ACTIVITY) | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-07-13 | — | — | WO | disclosed |
| EP-1016663-A1 | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity) | Aventis Pharma Deutschland GmbH (DE) | 2000-07-05 | — | — | EP | disclosed |
| EP-0061910-B1 | NOVEL SUBSTITUTED IMIDAZOLES AND TRIAZOLES, FUNGICIDAL COMPOSITIONS CONTAINING THEM, THE USE THEREOF FOR COMBATING FUNGI AND PROCESSES FOR THE PREPARATION OF INTERMEDIATES FOR MAKING THE IMIDAZOLES AND TRIAZOLES | ROHM AND HAAS COMPANY (US) | 1986-08-27 | — | — | EP | disclosed |
| EP-0061910-A2 | Novel substituted imidazoles and triazoles, fungicidal compositions containing them, the use thereof for combating fungi and processes for the preparation of intermediates for making the imidazoles and triazoles | ROHM AND HAAS COMPANY (US) | 1982-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022596-A1 | Novel malonic acid derivatives, processes for their preparation their use and pharmaceutical compositions containing them | F12, ME1, F11 | SLC6A4 4454/4885ALDH1A1 129/4885CYP2C9 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.